Microcap Ledger TuHURA Biosciences, Inc./NV $HURA
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Pharmaceutical Preparations
- Headquarters
- Tampa, FL
- Fiscal year end
- December 31
- Shares outstanding
- 63,726,617 [10-Q 2026-08-14]
What the company doesAI summary of filing
TuHURA Biosciences is a clinical-stage immuno-oncology company developing therapeutics to overcome resistance to cancer immunotherapies. The company's lead product, IFx-2.0, is an innate immune agonist delivered via intratumoral injection that is in a Phase 3 registration trial for advanced or metastatic Merkel cell carcinoma as an adjunctive therapy to pembrolizumab. Through the June 2025 acquisition of Kineta, Inc., TuHURA gained TBS-2025, a VISTA-inhibiting monoclonal antibody planned for Phase 1b/2 development in relapsed or refractory mutated NPM1 acute myeloid leukemia. The company is also developing Delta Opioid Receptor-targeted bi-functional, bi-specific antibody-drug conjugates designed to modulate myeloid-derived suppressor cells and overcome acquired resistance to immunotherapies. TuHURA is pre-revenue and operates as a development-stage biopharmaceutical company. [10-K 2026-03-31]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | — | −$16.76M | −$13.05M | $996.0K | [10-Q 2026-08-14] |
| FY ended Dec 2025 | $0.00 | −$31.00M | −$27.63M | $3.62M | [10-K 2026-03-31] |
| FY ended Dec 2024 | $0.00 | −$23.00M | −$14.73M | $12.66M | [10-K 2026-03-31] |
- Quarterly cash burn
- −$6.52M
- Cash runway Estimate
- ~0.5 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2025-03-31 | 43,680,397 | [10-K 2025-03-31] |
| 2025-05-12 | 43,680,396 | [10-Q 2025-05-15] |
| 2025-08-11 | 50,046,926 | [10-Q 2025-08-14] |
| 2025-11-11 | 51,258,085 | [10-Q 2025-11-14] |
| 2026-03-23 | 63,578,528 | [10-K 2026-03-31] |
| 2026-04-24 | 63,682,528 | [10-K/A 2026-04-30] |
| 2026-05-12 | 63,682,528 | [10-Q 2026-05-15] |
| 2026-08-11 | 63,726,617 | [10-Q 2026-08-14] |
- Shelf registration
- S-3 filed 2025-11-03; no effectiveness notice found in EDGAR [S-3 2025-11-03]
Listing status
Current status: 1 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2026-01-30. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.
| Date | Event | Details | Deadline | Filing |
|---|---|---|---|---|
| 2026-01-30 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2026-01-30] |
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-05-28 | Bianco James A. | other | 150,000 | — | [4 2026-05-29] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-09-24 | 8-K | New financial obligation |
| 2026-09-17 | 8-K | New financial obligation |
| 2026-09-17 | 8-K | Director or officer change |
| 2026-09-16 | 8-K | Director or officer change |
| 2026-09-04 | 8-K | New financial obligation |
| 2026-08-28 | 13D/A | Beneficial ownership report (5%+ holder) |
| 2026-08-21 | 8-K | New financial obligation |
| 2026-08-19 | 8-K | Unregistered sale of equity; Shareholder vote results |
| 2026-08-14 | 10-Q | Quarterly report |
| 2026-08-14 | 8-K | Results of operations |
| 2026-08-13 | 8-K | New financial obligation |
| 2026-07-29 | 8-K | New financial obligation |
Alerts for $HURA
Email me when TuHURA Biosciences, Inc./NV files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.